Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Ilaria Bertoldi,1 Roberto Caporali2 1Medical Department, Pfizer Italy, Rome, Italy; 2Department of Clinical Sciences and Community Health, University of Milan and ASST Pini-CTO Hospital, Milan, ItalyCorrespondence: Roberto CaporaliDepartment of Clinical Sciences and Community Health, University of M...

Full description

Bibliographic Details
Main Authors:	Bertoldi I, Caporali R
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-07-01
Series:	Open Access Rheumatology : Research and Reviews
Subjects:	rheumatoid arthritis real-world effectiveness persistence
Online Access:	https://www.dovepress.com/tofacitinib-real-world-data-and-treatment-persistence-in-rheumatoid-ar-peer-reviewed-fulltext-article-OARRR

Similar Items

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
by: Jennie H. Best, et al.
Published: (2020-03-01)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
by: Jean-Hugues Salmon, et al.
Published: (2020-05-01)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
by: Mahlich J, et al.
Published: (2016-08-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
by: V. I. Mazurov, et al.
Published: (2018-05-01)

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
by: Kawalec P, et al.
Published: (2017-12-01)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
by: Ruediger B. Mueller, et al.
Published: (2019-09-01)

Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt)
by: Ana Filipa Mourão, et al.
Published: (2017-04-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
by: Marta Madej, et al.
Published: (2019-08-01)

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
by: Teresa A. Simon, et al.
Published: (2019-11-01)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
by: Janet E. Pope, et al.
Published: (2019-04-01)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
by: Marina Amaral de Ávila Machado, et al.
Published: (2018-03-01)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients
by: María Ángeles González-Fernández, et al.
Published: (2019-01-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept
by: Al-Ani N, et al.
Published: (2021-04-01)

Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data
by: Paul Emery, et al.
Published: (2019-11-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib
by: Valentina Perrone, et al.
Published: (2020-07-01)

Tofacitinib in baseline treatment of rheumatoid arthritis: own clinical experience
by: A. R. Babaeva, et al.
Published: (2016-12-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)
by: A. S. Avdeeva, et al.
Published: (2020-06-01)

Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower
by: W. Benjamin Nowell, et al.
Published: (2021-02-01)

Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs
by: L. Degli Esposti, et al.
Published: (2021-04-01)

Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
by: Peter M. ten Klooster, et al.
Published: (2019-11-01)

Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
by: Ioannis Grigoropoulos, et al.
Published: (2019-01-01)

Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
by: Boyce EG, et al.
Published: (2016-01-01)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
by: Degli Esposti L, et al.
Published: (2016-12-01)

Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports
by: Astrid Wiens, et al.
Published: (2019-04-01)

JAK ACADEMY in Rheumatoid Arthritis (RA)
by: Roberto Caporali, et al.
Published: (2018-09-01)

Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis
by: Fakhouri W, et al.
Published: (2018-08-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports
by: Tetsuo Kobayashi, et al.
Published: (2019-04-01)

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp—A Usability Study
by: Savino Sciascia, et al.
Published: (2020-05-01)

The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry)
by: V. V. Rybakova, et al.
Published: (2021-07-01)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
by: Wataru Hirose, et al.
Published: (2021-08-01)

Barriers to treatment optimization and achievement of patients’ goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry
by: Kelly Gavigan, et al.
Published: (2020-01-01)